Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug gets a needle upgrade: shot form tested in advanced tumors

NCT ID NCT07015697

Recruiting now Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 36 times

Summary

This early-stage trial tests a new way to give the cancer drug trastuzumab deruxtecan (T-DXd) as a shot under the skin instead of through an IV. It aims to see if the shot is safe and works well in people with metastatic solid tumors that have spread. About 76 adults with advanced cancers will take part to help find the right dose and check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Newport Beach, California, 92663, United States

  • Research Site

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Research Site

    RECRUITING

    Las Vegas, Nevada, 89169, United States

  • Research Site

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Research Site

    RECRUITING

    Maumee, Ohio, 43537, United States

  • Research Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Research Site

    RECRUITING

    Rennes, France

  • Research Site

    RECRUITING

    Chiba, Japan

  • Research Site

    RECRUITING

    Kanagawa, 241-8515, Japan

  • Research Site

    RECRUITING

    Tokyo, 104-0045, Japan

  • Research Site

    RECRUITING

    Tokyo, 135-8550, Japan

  • Research Site

    RECRUITING

    Tokyo, 142-8666, Japan

  • Research Site

    RECRUITING

    Seongnam-si, South Korea

  • Research Site

    RECRUITING

    Seoul, 03722, South Korea

  • Research Site

    RECRUITING

    Seoul, 06351, South Korea

  • Research Site

    RECRUITING

    Seoul, 3080, South Korea

  • Research Site

    RECRUITING

    Seoul, South Korea

  • Research Site

    RECRUITING

    Barcelona, Spain

  • Research Site

    RECRUITING

    Madrid, Spain

  • Research Site

    RECRUITING

    Seville, Spain

  • Research Site

    RECRUITING

    Taichung, Taiwan

  • Research Site

    RECRUITING

    Tainan, Taiwan

  • Research Site

    RECRUITING

    Taipei, 10002, Taiwan

  • Research Site

    RECRUITING

    Taipei, Taiwan

  • Research Site

    RECRUITING

    Taoyuan City, Taiwan

  • Research Site Saint

    RECRUITING

    Herblain, France

Conditions

Explore the condition pages connected to this study.

RECURRENT OR METASTATIC SOLID TUMORS